Search Result
Results for "
antibiotics resistance
" in MedChemExpress (MCE) Product Catalog:
3
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-106681
-
Fungichromin; Pentamycin; Cogomycin
|
Antibiotic
Fungal
|
Cancer
|
Lagosin (Fungichromin) is a polyene macrolide antibiotic. Lagosin has demonstrated broad-spectrum antifungal activity and is impervious to agent resistance .
|
-
-
- HY-77641
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment .
|
-
-
- HY-W062216
-
|
Bacterial
Arginase
|
Infection
|
2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits. 2-Aminoimidazole is also a weak noncompetitive inhibitor of human arginase I with a Ki of 3.6 mM .
|
-
-
- HY-P1674A
-
POL7080 TFA
|
Bacterial
Antibiotic
|
Infection
|
Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with MIC50 and MIC90 values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
|
-
-
- HY-146199
-
|
Bacterial
|
Infection
|
Antibacterial agent 108 (Compound 1h) is a potent antibacterial agent with a MIC of both 3 μM against MRSA and antibiotic resistance strains .
|
-
-
- HY-77641R
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cinnamoylglycine (Standard) is the analytical standard of Cinnamoylglycine. This product is intended for research and analytical applications. Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment .
|
-
-
- HY-155504
-
|
Beta-lactamase
Bacterial
|
Infection
|
Metallo-β-lactamase-IN-11 (compound 5f) is a Metallo-β-lactamases (MBLs) inhibitor, potent against bacterial metallophyllactamase CphA (IC50=45 µM). Metallo-β-lactamase-IN-11 (10 µM) inhibits NDM-1 by 49% and AIM-1 by 61%. Metallo-β-lactamase-IN-11 can be used in the research of inhibiting antibiotic resistance .
|
-
-
- HY-P10027
-
|
Antibiotic
Bacterial
|
Infection
|
Clovibactin is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
|
-
-
- HY-P1674
-
POL7080
|
Bacterial
Antibiotic
|
Infection
|
Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with both MIC50 and MIC90 values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
|
-
-
- HY-P10211
-
|
Antibiotic
Bacterial
|
Infection
|
Virgilagicin is a Gram-positive active antibiotic that has a dual polyprenyl phosphate binding mechanism that impedes resistance development .
|
-
-
- HY-P10209
-
|
Antibiotic
Bacterial
|
Infection
|
Cilagicin, a dodeca-lipodepsipeptide, is a Gram-positive active antibiotic. Cilagicin has a dual polyprenyl phosphate binding mechanism that impedes resistance development .
|
-
-
- HY-13554
-
|
Antibiotic
|
Infection
Cancer
|
Annamycin is an antibiotic, that has high affinity for lipid membranes and can bypass the multidrug resistance protein-1 (MDR-1 ) mechanism of cellular drug resistance. Annamycin exhibits antitumor efficacy in multilamellar vesicles against solid tumor .
|
-
-
- HY-119206
-
|
Antibiotic
|
Others
|
Sulbenicillin is an antibiotic that, in a study of its activity against Pseudomonas aeruginosa infection in mice, showed differences in activity against certain strains compared to other antibiotics, and activity against gentamicin-resistant strains was affected by the strain's own resistance.
|
-
-
- HY-B1329
-
Nebramycin II sulfate
|
Bacterial
Antibiotic
|
Infection
|
Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
|
-
-
- HY-126906
-
|
Antibiotic
P-glycoprotein
|
Cancer
|
Milbemycin A4 inhibits P-glycoprotein activity, and reverses multidrug resistance of tumor cells. Milbemycins are a family of macrolide antibiotics with insecticidal and acaricidal activity sup>[2].
|
-
-
- HY-P5620
-
|
Bacterial
|
Infection
|
DFTamP1 is an antimicrobial peptide against Staphylococcus aureus USA300 activity (MIC is 3.1 μM) .
|
-
-
- HY-161685
-
-
-
- HY-16752A
-
MK-7655 sodium
|
Beta-lactamase
Bacterial
|
Infection
|
Relebactam sodium (MK-7655 sodium) is a potent and selective β-lactamase inhibitor with the activity of delaying the development of bacterial resistance to antibiotics. Relebactam sodium can bind to a variety of β-lactamases, thereby improving the efficacy of β-lactam antibiotics. Relebactam sodium shows good application potential in inhibiting complicated bacterial infections .
|
-
-
- HY-100589
-
Sch 21420 sulfate
|
Bacterial
Antibiotic
|
Infection
|
Isepamicin sulfate (Sch 21420 sulfate) is a broad spectrum aminoglycoside antibiotic. Isepamicin sulfate exhibits considerable antimicrobial activity against Gram-negative non-fermenters in a region with high antimicrobial resistance .
|
-
-
- HY-168799
-
-
-
- HY-P10210
-
|
Antibiotic
Bacterial
|
Infection
|
Paenilagicin is a Gram-positive active antibiotic with a unique diphosphorylated prenyl binding mechanism that does not induce drug resistance. Paenilagicin exhibits a MIC value of 2 μg/mL against multidrug-resistant Gram-positive bacteria .
|
-
-
- HY-B1329R
-
|
Bacterial
Antibiotic
|
Infection
|
Apramycin (sulfate) (Standard) is the analytical standard of Apramycin (sulfate). This product is intended for research and analytical applications. Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
|
-
-
- HY-167841
-
|
Bacterial
Antibiotic
|
Infection
|
Anti-MRSA agent 19 (Compound 1) is an antibiotic that exhibits activity against S. aureus. Anti-MRSA agent 19 is a active (median MIC=4 μg/mL) against 40 CDC isolates of different bacterial species containing various resistance factors, including Vancomycin (HY-B0671), aminoglycoside/Tetracycline (HY-A0107), and oxazolidinone resistance .
|
-
-
- HY-77641S
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cinnamoylglycine-d2 is the deuterium labeled Cinnamoylglycine. Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment[1].
|
-
-
- HY-P10027A
-
|
Antibiotic
Bacterial
|
Infection
|
Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
|
-
-
- HY-149333
-
|
Bacterial
|
Infection
|
BO-1 is a benzoate ester with antibacterial activity. BO-1 inhibits multidrug-resistant Staphylococcus aureus, and acts function synergistically with antibiotic, such as Ciprofloxacin (HY-B0356). BO-1 can reverse the resistance of antibiotic-resistant S. aureus strains, and decreases the level of inflammatory factors IL-6 and C-reactive protein in vivo in mice .
|
-
-
- HY-146330
-
|
Bacterial
|
Infection
|
FtsZ-IN-2 (Compound 19) is an inhibitor of the bacterial cell division protein FtsZ with GTPase inhibitory activity. FtsZ-IN-2 exhibits anti-staphylococcal activity with MIC values of 2 µg/ml for MSSA and MRSA .
|
-
-
- HY-156414
-
-
-
- HY-P10411
-
|
Bacterial
|
Infection
|
BING is an antimicrobial peptide that can be isolated from Japanese medaka fish. BING shows a broad-spectrum toxicity against pathogenic bacteria including drug-resistant strains. BING induces a deregulation of periplasmic peptidyl-prolyl isomerases in gram-negative bacteria, and reduces the RNA level of cpxR, which plays a crucial role in the development of antimicrobial resistance .
|
-
-
- HY-118043
-
|
Antibiotic
|
Infection
|
RK-1441B is an anti-phage antibiotic produced by Streptomyces sp. RK-1441 and belongs to the pyrrolo[1,4]benzodiazepine class. RK-1441B has antiphage activity but no significant antimicrobial activity against a supersusceptible E. coli strain to an antitumor antibiotic. RK-1441B is inactive in vitro and may be converted to the active form in the host organism. Its fellow antibiotic RK-1441A can form an adduct with guanine residues in the DNA chain to exert resistance .
|
-
-
- HY-126906R
-
|
Antibiotic
P-glycoprotein
|
Cancer
|
Milbemycin A4 (Standard) is the analytical standard of Milbemycin A4. This product is intended for research and analytical applications. Milbemycin A4 inhibits P-glycoprotein activity, and reverses multidrug resistance of tumor cells. Milbemycins are a family of macrolide antibiotics with insecticidal and acaricidal activity sup> .
|
-
-
- HY-127146
-
|
Antibiotic
Bacterial
|
Infection
|
Platensimycin is an antibiotic produced by S. platensis that inhibits gram-positive bacteria by selectively inhibiting cellular lipid biosynthesis (IC50=0.1 μM). Platensimycin targets the β-ketoacyl-acyl-carrier-protein synthase I/II, FabF/B, an enzyme that participates in the biosynthesis of fatty acids (IC50s=48 nM and 160 nM for S.aureus and E.coli enzymes, respectively). Platensimycin is a promising agent for overcoming antibiotic resistance.
|
-
-
- HY-B1599
-
|
Bacterial
Antibiotic
|
Infection
|
Chloramphenicol palmitate is an orally active broad spectrum antibiotic and has a broad spectrum of activity against gram positive and gram negative bacteria. Chloramphenicol palmitate inhibits bacterial protein synthesis by blocking the peptidyl transferase step. Chloramphenicol palmitate can be used as bacterial selection agent in transformed cells containing chloramphenicol resistance genes .
|
-
-
- HY-130337
-
|
Antibiotic
Bacterial
|
Infection
|
Teicoplanin A2-2 is a glycopeptide antibiotic. Teicoplanin A2-2 exhibits antibacterial activity, particularly against coagulase-negative staphylococci (CNS). Teicoplanin A2-2 inhibits bacterial cell wall synthesis by competitively binding to the terminal D-Ala-D-Ala peptide bonds in the cell wall synthesis process, leading to bacterial death. Teicoplanin A2-2 can be used for research into bacterial resistance mechanisms and the development of new antibiotics .
|
-
-
- HY-19160
-
PA-1806; BMS 180680-01
|
Antibiotic
Bacterial
|
Infection
|
BMS-180680 (PA-1806) is an antibiotic, which exhibits a board-spectrum antibacterial activity against gram-negative bacteria. BMS-180680 inihibits Pseudomonas aeruginosa with MIC of 0.25 µg/ml. BMS-180680 exhibits resistance to hydrolysis by β-lactamases, such as TEM-2 and PSE enzymes .
|
-
-
- HY-106668
-
Sch 21420
|
Antibiotic
Bacterial
|
Infection
|
Isepamicin (Sch 21420) is an aminoglycoside antibacterial. Isepamicin has better activity against strains producing type I 6'-acetyltransferase. Isepamicin’s antibacterial spectrum includes Enterobacteriaceae and staphylococci. Anaerobes, Neisseriaceae and streptococci are resistant. Isepamicin exhibits a strong concentration-dependent bactericidal effect, a long post-antibiotic effect (several hours) and induces adaptive resistance .
|
-
-
- HY-N12727
-
|
Bacterial
|
Infection
|
Okaramine I is an Escherichia coli glycosyltransferase (MurG) inhibitor. Okaramine I can be used as an antibacterial agent. Okaramine I can be found in Aspergillus aculeatus .
|
-
-
- HY-159687
-
WCK 4873
|
Antibiotic
Bacterial
|
Infection
|
Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC90 of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter .
|
-
-
- HY-168511
-
|
DNA/RNA Synthesis
Bacterial
|
Infection
|
DNA Gyrase-IN-13 (compound 1b) is a DNA Gyrase inhibitor. DNA Gyrase-IN-13 has antibacterial activity. DNA Gyrase-IN-13 has an IC50 value of 1.81 μM for Staphylococcus aureus DNA gyrase .
|
-
-
- HY-B1241A
-
DHSM
|
Antibiotic
|
Others
|
Dihydrostreptomycin (DHSM) is an antibiotic that exhibits resistance to penicillin in strains of Pseudomonas lachrymans. Studies have shown that these strains can inactivate DHSM using a cell-free system in the presence of disodium adenosine triphosphate. The inactivated DHSM can be regenerated by alkaline phosphatase but not by phosphodiesterase. The structure of the inactivated DHSM has been determined by methods such as proton magnetic resonance imaging, and it was found that the hydroxyl group at the C-3 position of DHSM in its chemical structure is phosphorylated by the enzyme. Therefore, the study suggests that ATP:aminoglycoside 3"-phosphotransferase plays a role in DHSM resistance in Pseudomonas lachrymans N-7641 .
|
-
-
- HY-B1455
-
|
Bacterial
Antibiotic
Parasite
|
Infection
Cancer
|
Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
|
-
-
- HY-B0337B
-
Sulphadimethoxine 1000 µg/mL in methanol
|
Antibiotic
|
Infection
|
Sulfadimethoxine 1000 μg/mL in methanol (Sulphadimethoxine 1000 μg/mL in methanol) is a sulfonamide antibiotic that inhibits the enzyme dihydropteroate synthase, thereby blocking dihydrofolic acid synthesis and disrupting folic acid production in prokaryotic organisms. Its antimicrobial activity extends to both Gram-positive and Gram-negative bacteria, as well as Chlamydia. Resistance to this compound may arise through alterations in dihydropteroate synthase or the activation of alternative pathways for folic acid synthesis.
|
-
-
- HY-116815
-
|
Beta-lactamase
Bacterial
|
Infection
Neurological Disease
|
Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .
|
-
-
- HY-B1455S
-
|
Bacterial
Antibiotic
Parasite
|
Infection
|
Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].
|
-
-
- HY-B1455R
-
|
Bacterial
Antibiotic
Parasite
|
Infection
Cancer
|
Clindamycin (Standard) is the analytical standard of Clindamycin. This product is intended for research and analytical applications. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
|
-
-
- HY-B1599R
-
|
Bacterial
Antibiotic
|
Infection
|
Chloramphenicol palmitate (Standard) is the analytical standard of Chloramphenicol palmitate. This product is intended for research and analytical applications. Chloramphenicol palmitate is an orally active broad spectrum antibiotic and has a broad spectrum of activity against gram positive and gram negative bacteria. Chloramphenicol palmitate inhibits bacterial protein synthesis by blocking the peptidyl transferase step. Chloramphenicol palmitate can be used as bacterial selection agent in transformed cells containing chloramphenicol resistance genes .
|
-
-
- HY-N7118
-
|
Bacterial
Antibiotic
|
Infection
Cancer
|
Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .
|
-
-
- HY-150766
-
|
Bacterial
|
Infection
|
KPC-2-IN-1, boronic acid derivative, is a potent KPC-2 inhibitor with Ki of 0.032 μM. KPC-2-IN-1 enhances the activity of cefotaxime in KPC-2 expressing E. coli. KPC-2-IN-1 exhibits well tolerated in human HEK-293 cells, which can be used for the study of E. coli resistance to β-lactam antibiotics .
|
-
-
- HY-162174
-
|
Beta-lactamase
Bacterial
|
Infection
|
MBL-IN-2 ((2R, 2R')-5αC) is an inhibitor of Metallo-β-lactamase (MBL) that can inhibit New Delhi Metallo-β-lactamase-1 (NDM-1) with an IC50 of 0.3 μM. MBL-IN-2 ((2R, 2R')-5αC) can be used for the study of resistance to β-lactam antibiotics .
|
-
-
- HY-B0317F
-
|
Calcium Channel
|
Infection
|
Amlodipine hydrochloride is a biologically active drug used to lower blood pressure and prevent chest pain. Amlodipine hydrochloride has shown synergistic effects with antimicrobial drugs in in vitro studies, especially against carbene peptide-resistant Acinetobacter baumannii. Amlodipine hydrochloride can be used in combination with other antibiotics to enhance the inhibitory effect against resistant bacteria. The use of amlodipine hydrochloride helps reduce the dosage requirements of the drug, reduce toxic effects, and delay the emergence of drug resistance .
|
-
- HY-B1455S1
-
|
Isotope-Labeled Compounds
Bacterial
Antibiotic
Parasite
|
Infection
|
Clindamycin- 13C,d3 is the 13C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2][3].
|
-
- HY-P3078
-
|
Bacterial
Antibiotic
|
Infection
|
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
|
-
- HY-106922
-
GV104326
|
Antibiotic
Bacterial
|
Infection
|
Sanfetrinem (GV104326) is a β-lactamase-stable antibiotic. Sanfetrinem has broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria .
|
-
- HY-116598
-
GSK 1322322 mesylate
|
Bacterial
|
Infection
|
Lanopepden mesylate (GSK 1322322 mesylate) is a peptide deformase (PDF) inhibitor. Lanopepden mesylate has antibacterial activity by inhibiting the activity of PDF, preventing the correct synthesis of bacterial proteins. Lanopepden mesylate mainly targets Gram-positive bacteria. Lanopepden mesylate can be used in the study of acute bacterial skin and skin structural infections .
|
-
- HY-144659
-
|
Beta-lactamase
Apoptosis
Bacterial
|
Infection
|
Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC50 of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity .
|
-
- HY-168281
-
|
Bacterial
|
Infection
|
P6P-10,10 is an antimicrobial agent. P6P-10,10 has an IC50 value of 3 μM against colistin-resistant Acinetobacter baumannii .
|
-
- HY-N7118R
-
|
Bacterial
Antibiotic
|
Infection
Cancer
|
Clindamycin (hydrochloride monohydrate) (Standard) is the analytical standard of Clindamycin (hydrochloride monohydrate). This product is intended for research and analytical applications. Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .
|
-
- HY-147531
-
|
Bacterial
|
Infection
|
Antibacterial agent 106 (compound 8) is an orally active and potent antibacterial agent with antibiofilm activity. Antibacterial agent 106 shows potent antibacterial effect against multi-agent resistant (MDR)-Gram positive pathogens. Antibacterial agent 106 is highly effective in clearing 99.7% of the intracellular methicillin-resistant S. aureus (MRSA) harbored inside macrophages . Antibacterial agent 106 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-147674
-
|
Aminoacyl-tRNA Synthetase
|
Infection
|
Isoleucyl tRNA synthetase-IN-2 (compound 36a) is a potent and selective isoleucyl-tRNA synthetase (IleRS) inhibitor, with a Ki,app of 114 nM .
|
-
- HY-147671
-
-
- HY-147672
-
-
- HY-129262
-
|
Antibiotic
Bacterial
|
Infection
|
Deoxypheganomycin D is a specific antimycobacterial inhibitor with no cross-resistance to other antibiotics such as Paromomycin (HY-B0956), Capreomycin (HY-P3270), Viomycin (HY-A0155), Streptothricin (HY-129065), Kanamycin (HY-16566), and Streptomycin (HY-B1906). Deoxypheganomycin D (28 μM) partially inhibits the growth of Mycobacterium 607, with no significant inhibitory effects on DNA, RNA, or protein synthesis. Deoxypheganomycin D (7 μM) affects leucine influx, not thymidine, and has the opposite effect on efflux. The effects of Deoxypheganomycin D may be related to cell membrane and specific mycobacterial lipid components.
|
-
- HY-103251
-
LpxC-4
|
Antibiotic
Bacterial
|
Infection
|
PF-5081090 (LpxC-4) is a potent LpxC inhibitor, is a rapidly bactericidal with broad-spectrum activity. PF-5081090 serves as a regulator of lipid A biosynthesis in Gram-negative pathogens .
|
-
-
-
HY-L169
-
|
448 compounds
|
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important.
MCE designs a unique collection of 448 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1674A
-
POL7080 TFA
|
Bacterial
Antibiotic
|
Infection
|
Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with MIC50 and MIC90 values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
|
-
- HY-P10027A
-
|
Antibiotic
Bacterial
|
Infection
|
Clovibactin TFA is the TFA salt form of Clovibactin (HY-P10027). Clovibactin TFA is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
|
-
- HY-P10027
-
|
Antibiotic
Bacterial
|
Infection
|
Clovibactin is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
|
-
- HY-P1674
-
POL7080
|
Bacterial
Antibiotic
|
Infection
|
Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with both MIC50 and MIC90 values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance .
|
-
- HY-P10211
-
|
Antibiotic
Bacterial
|
Infection
|
Virgilagicin is a Gram-positive active antibiotic that has a dual polyprenyl phosphate binding mechanism that impedes resistance development .
|
-
- HY-P10209
-
|
Antibiotic
Bacterial
|
Infection
|
Cilagicin, a dodeca-lipodepsipeptide, is a Gram-positive active antibiotic. Cilagicin has a dual polyprenyl phosphate binding mechanism that impedes resistance development .
|
-
- HY-P5620
-
|
Bacterial
|
Infection
|
DFTamP1 is an antimicrobial peptide against Staphylococcus aureus USA300 activity (MIC is 3.1 μM) .
|
-
- HY-P10210
-
|
Antibiotic
Bacterial
|
Infection
|
Paenilagicin is a Gram-positive active antibiotic with a unique diphosphorylated prenyl binding mechanism that does not induce drug resistance. Paenilagicin exhibits a MIC value of 2 μg/mL against multidrug-resistant Gram-positive bacteria .
|
-
- HY-P10411
-
|
Bacterial
|
Infection
|
BING is an antimicrobial peptide that can be isolated from Japanese medaka fish. BING shows a broad-spectrum toxicity against pathogenic bacteria including drug-resistant strains. BING induces a deregulation of periplasmic peptidyl-prolyl isomerases in gram-negative bacteria, and reduces the RNA level of cpxR, which plays a crucial role in the development of antimicrobial resistance .
|
-
- HY-P3078
-
|
Bacterial
Antibiotic
|
Infection
|
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B1455S1
-
|
Clindamycin- 13C,d3 is the 13C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2][3].
|
-
-
- HY-77641S
-
|
Cinnamoylglycine-d2 is the deuterium labeled Cinnamoylglycine. Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment[1].
|
-
-
- HY-B1455S
-
|
Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: